Oral management of the patient with end-stage liver disease and the liver transplant patient

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 86, Issue 1, 1998, Pages 55-64

  Douglas, Lindsey R ^a   Douglass, J Burton ^a   Sieck, Jens Otto ^a   Smith, Phillip J ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL ENDOCARDITIS; DENTAL CARE; DRUG INTERACTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; MOUTH DISEASE; OPPORTUNISTIC INFECTION; REVIEW; RISK FACTOR; TOOTH DISEASE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DENTAL CARE; DRUG INTERACTIONS; ENDOCARDITIS, BACTERIAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MOUTH DISEASES; OPPORTUNISTIC INFECTIONS; RISK FACTORS; TOOTH DISEASES;

EID: 0032113795     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(98)90150-0     Document Type: Article

References (95)

1. Terasaki PI, Cecka JM, editors. Clinical transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory; 1994. p. 704.
2. Starzl TE, Demetris AJ. Liver transplantation: a 31-year perspective, III. Curr Probl Surg 1990;4:183-240.
3. Busuttil RW, Shaked A, Millis JM. One thousand liver transplants: the lessons learned. Ann Surg 1994:219-490.
4. Asfar S, Metrakos P, Fryer J, Verran D, Ghent C, Grant D, et al. An analysis of late deaths after liver transplantation. Transplantation 1996;61:1377-81.
5. Little JW, Rhodus NL. Dental treatment of the liver transplant patient [review]. Oral Surg Oral Med Oral Pathol 1992;73:419-26.
6. Beirne OR, Koehler JR. Surgical management of patients on warfarin sodium. J Oral Maxillofac Surg 1996;54:1115-8.
7. Ziccardi VB, Abubaker AO, Sotereanos GC, Patterson GT. Maxillofacial considerations in orthotopic liver transplantation. Oral Surg Oral Med Oral Pathol 1991;71:21-6.
8. Rose L, Kay D. Internal medicine for dentistry. St. Louis: Mosby; 1983. p. 425-6.
9. Svirsky JA, Saravia ME. Dental management of patients after liver transplantation. Oral Surg Oral Med Oral Pathol 1989;67:541-6.
10. Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S, et al. Fungal infections in liver transplant recipients. Transplantation 1985;40:347-53.
11. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988;67:132-43.
12. Hoefs MD. Spontaneous bacterial peritonitis: prevention and therapy [editorial]. Hepatology 1990;12:776-81.
13. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
14. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its rela-tionship to bacterial infections and prognosis. Hepatology 1984;4:53-8.
15. Hoefs JC, Runyon BA. Spontaneois bacterial peritonitis. Dis Mon 1985;31:1-48.
16. Lockhart PB. An analysis of bacteremias during dental extractions. Arch Intern Med 1996;156:513-20.
17. Lockhard PB, Schmidtke MA. Antibiotic considerations in medically compromised patients. Dent Clin North Am 1994;38:381-402.
18. Schlaeffer F, Riesenberg K, Mikolich D, Sikuler E, Niv Y. Serious bacterial infections after endoscopic proceedures. Arch Intern Med 1996;156:572-4.
19. Norfleet RG, Mitchell PD, Mulholland DD. Does bacterimia follow upper gastrointestinal endoscopy. Am J Gastroenterol 1981;76:420-2.
20. Van Happs D, Strickland R, Willliams CR. Inhibitors of leukocyte chemotaxis in alcoholic liver disease. Am J Med 1975;59:200-7.
21. Durack DT, Phil D. Prevention of infective endocarditis. N Eng J Med 1995;332:38-43.
22. Bennett WM, Norman DJ. Action and toxicity of cyclosporine [review]. Annu Rev Med 1986;37:215-24.
23. Starzl TE, Imatsuki S, Shaw BWJ. Orthotopic liver transplantation in 1984. Transplant Proc 1985;17:250-8.
24. Kronke M, Leonard W, Depper JM. Cyclosporine A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A 1984;74:5214-8.
25. Rosano TG, Freed BM, Cerilli J, Lempert N. Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation 1986;42:262-7.
26. Ruskin JD, Wood RP, Bailey MR, Whitmore CK, Shaw BW. Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis prophylaxis in orthotopic liver transplant patients. Oral Surg Oral Med Oral Pathol 1992;74:567-71.
27. Munoz SJ, Maddrey WC. Transplantation of the liver. In: Rector WG, editor. Complications of chronic liver disease. St. Louis: Mosby-Year Book; 1992. p. 339-71.
28. Colonna JO, Winston DJ, Brill JE, Goldstein, LI, Hoff MP, Hiatt JR, et al. Infectious complications in liver transplantation. Arch Surg 1988;123:360-4.
29. Fulginiti VA, Scribner R, Groth CG, Putnam CW, Brettschneider L, Gilbert S, et al. Infections in recipients of liver homografts. N Eng J Med 1968;279:619-26.
30. Dreezen S. Oral candidiasis. Am J Med 1984;77:28-33.
31. Trier JS, Bjorkman DJ. Esophageal, gastric, and intestinal candidiasis. Am J Med 1984;77:39-43.
32. Stone HH, Geheber CE, Kolb LD. Alimentary tract colonization by cabduda albicans. J Surg Res 1973;44:479-92.
33. Inoue S, Wirman JA, Alexander JW, Trocki O, Cardell RR. Candida albicans translocation across the gut mucosa following burn injury. J Surg Res 1988;44:479-92.
34. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983;36:259-67.
35. Barkholt LM, Ericzon BG, Ehrnst A, Forsgren M, Andersson JP. Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc 1990;22:235-7.
36. van den Berg AP, van Son WJ, Jiwa NM, van der Bijl W, Schirm J, van der Giessen M, et al. Recent advances in the diagnosis of active Cytomegalovirus infection after organ transplantation. Transplant Proc 1990;22:226-8.
37. Epstein JB, Sherlock CH, Wolber RA. Oral manifestations of cytomegalovirus infection. Oral Surg Oral Med Oral Pathol 1993;75:443-51.
38. Rubin RH. Infection in the renal and liver transplant patient. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. 2nd ed. New York: Plenum Medical Book Co.; 1988. p. 557-621.
39. Paya CV, Hermans PE, Smith TF, Rakela J, Wiesner RH, Krom RA, et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 1988;46:229-34.
40. Feldhoff CM, Reber T, Drachman R, Drukker A. Skin and mucosal lesions associated with cyclosporin A therapy: report of a case. Clin Nephrol 1989;31:210-2.
41. Qunibi WY, Akhtar M, Ginn E, Smith P. Kaposi's sarcoma in cyclosporine-induced gingival hyperplasia. Am J Kidney Dis 1988;11:349-52.
42. Alessiani M, Kusne S, Martin FM, Fung JJ, Jain A, Todo S, et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc 1990;1:44-6.
43. Ross PJ, Nazif MM, Zullo T, Zitelli B, Guevara P. Effects of Cyclosporin A on gingival status following liver transplantation [review], ASDC J Dent Child 1989;56:56-9.
44. Itin P, Rufli T, Rudlinger R, Cathomas G, Huser B, Podvinec M, et al. Oral hairy leukoplakia in a HIV-negative renal transplant patient: a marker for immunosuppression? Dermatologica 1988;177:126-8.
45. Wood RP, Shaw BW Jr., Williams L. The use of OKT3 rescue therapy after orthotopic liver transplantation: the University of Nebraska Medical Center experience. Transplant Proc 1988;20: 254-9.
46. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987;43:91-5.
47. Demetris AJ, Fung JJ, Todo S, Banner B, Zerbe T, Sysyn G, et al. Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc 1990;22:25-34.
48. Wise R, Wright N. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. Infection 1985;13:S145-50.
49. Braveny I. In vitro activity of imipenem: a review. Eur J Clin Microbiol Infect Dis 1984;3:456-62.
50. Buckley MM, Barradell LB, Goa KL. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and theraputic efficacy. Drugs 1992;44:408-44.
51. Rolando NW, Wade JJ, Philpott-Howard JN, Casewell MW, Williams R. The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. J Antimicrob Chemother 1994;33:163-7.
52. Minah GE, Rednor JL, Peterson DE, Overholser CD, Depaola LG, Suzuki JB. Oral sucession of gram-negative bacilli in myelosuppresses cancer patients. J Clin Microbiol 1986;24:210-3.
53. Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients, emergence of gramnegative bacilli. N Engl J Med 1969;281:1137-40.
54. Galili D, Donitza A, Garfunkle A, Sela MN. Gram-negative enteric bacteria in the oral cavity of leukemia patients. Oral Surg Oral Med Oral Pathol 1992;74:459-62.
55. Moore R, Smith C, Lietman P. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986;80:1093-7.
56. Sands M, Brown RB. Interactions of cyclosporine with antimicrobial agents [review]. Rev Infect Dis 1989;11:691-7.
57. Kureishi A, Jewesson PJ, Rubinger M, Cole CD, Reece DE, Phillips GL, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991;35:2246-52.
58. Hospital Infection Control Advisory Committee (HICAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
59. Montecalvo MA, Horowitz H, Gedris C, Carbonaro F, Tenover C, Issah A, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
60. Eng RH, Gorski S, Person A, Mangura C, Chmel H. Clindamycin elimination in patients with liver disease. J Antimicrob Chemother 1981;8:277-81.
61. Elmore M, Rissing IP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med 1974;57:627-30.
62. Lau AH, Evans R, Chang C, Seligsohn R. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother 1987;31:1662-4.
63. Farrell G, Baird-Lambert I, Cvejic M, Buchanan N. Disposition and metabolism of metronidazole in patients with liver failure. Hepatology 1984;4:722-6.
64. Plaisance KI, Quintiliani R, Nightingale CH. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 1988;21:195-200.
65. Stambaugh JE, Feo LG, Manthei RW. The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther 1968;161:373-81.
66. Barre G, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis: respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987;6:753-7.
67. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985;16:181-94.
68. McCormack AJ, Snipes RG, Dillon JJ, Yang JJ, Finn WF. Primary renovascular effects of erythromycin in the rat: relationship to cyclosporine nephrotoxicity. Ren Fail 1990;12:241-8.
69. Jensen CW, Flechner SM, Van Buren CT, Frazier OH, Cooley DA, Lorber MI, et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 1987;43:263-70.
70. Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475-81.
71. Billaud EM, Guillemain R, Fortineau N, Kitzis MD, Dreyfus G, Amrein C, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990;19:499-502.
72. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
73. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibiotics. Drug Saf 1993;9:346-64.
74. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Antilymphocytic activity of erythromycin distinct from that of FK506. J Antibiot 1993;46:1406-13.
75. Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther 1974;16:667-75.
76. Patwardhan RV, Johnson RF, Hoyumpa A Jr, Sheehan JJ, Desmond PV, Wilkinson GR, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981;81:1006-11.
77. Csete M, Sullivan JB. Vicodin induced fulminant hepatic failure. Anesthesiology 1994;7:857-60.
78. Black M. Acetaminophen hepatotoxicity. Gastroenterology 1980;78:382-92.
79. Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979;26:483-92.
80. Gabrielle L, Leterrier F, Molinie C, Essioux H, Cristau P, Laverdant C. Determination of human liver cytochrome P-450 by a micromethod using the electron paramagnetic resonance: study of 141 liver biopsies [author's translation]. Gastroenterol Clin Biol 1977;1:775-82.
81. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis, 3: Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 1973;187:203-10.
82. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983;33:95-101.
83. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-50.
84. Bakti G, Fisch HU, Karlanganis G, Minder C, Bircher J. Mechanism of the excessive sedative responce of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987;7:629-38.
85. Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989;29:272-7.
86. Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976;84:420-5.
87. Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978;24:411-9.
88. Physicians desk reference. Montivale: Medical Economics Data; 1993. p. 619.
89. Ghoneim MM, Korttila K. Pharmacokinetics of intravenous anaesthetics: implications for clinical use. Clin Pharmacokinet 1977;2:344-72.
90. Pandele G, Chaux F, Salvadori C, Farinotti M, Duvaldestin P. Thiopental pharmacokinetics in patients with cirrhosis. Anesthesiology 1983;59:123-6.
91. Duvaldestin P, Chauvin M, Lebrault C, Bertrand F, Karolak FT, Farinotti R. Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital. Acta Anaesthesiol Scand 1991;35:159-63.
92. Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol [review]. Clin Pharmacokinet 1989;17:308-26.
93. Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 1988;18:429-40.
94. Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, Farinotti R. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 1988;69:887-91.
95. Servin F, Cockshott ID, Farinotti R, Haberer JP, Winckler C, Desmonts JM. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990;65:177-83.